BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 12629350)

  • 1. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
    Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
    Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.
    Nam RK; Elhaji Y; Krahn MD; Hakimi J; Ho M; Chu W; Sweet J; Trachtenberg J; Jewett MA; Narod SA
    J Urol; 2000 Aug; 164(2):567-72. PubMed ID: 10893645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
    Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
    J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women.
    Brum IS; Spritzer PM; Paris F; Maturana MA; Audran F; Sultan C
    J Soc Gynecol Investig; 2005 Feb; 12(2):135-41. PubMed ID: 15695110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
    Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
    Qiu YQ; Leuschner I; Braun PM
    Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer.
    Kuasne H; Rodrigues IS; Fuganti PE; Losi-Guembarovski R; Ito K; Kishima MO; Rodrigues MA; Rogatto SR; Santos RM; Cólus IM
    Cancer Invest; 2010 Nov; 28(9):917-24. PubMed ID: 20632874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CAG microsatellite polymorphisms of androgen receptor gene and the stage and grade of prostate cancer].
    Li C; Dong J; Guan W
    Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):217-9. PubMed ID: 11783090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.